Dogwood Therapeutics Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 8

Employees

  • Stock Symbol
  • DWTX

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.05
  • (As of Monday Closing)

Dogwood Therapeutics General Information

Description

Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.

Contact Information

Website
www.dwtx.com
Formerly Known As
Innovative Med Concepts, Virios Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 44 Milton Avenue
  • Alpharetta, GA 30009
  • United States
+1 (866)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 44 Milton Avenue
  • Alpharetta, GA 30009
  • United States
+1 (866)

Dogwood Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dogwood Therapeutics Stock Performance

As of 16-Nov-2026, Dogwood Therapeutics’s stock price is $1.05. Its current market cap is $40.5M with 38.2M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.05 $1.11 $0.90 - $7.04 $40.5M 38.2M 85.4K -$0.89

Dogwood Therapeutics Financials Summary

As of 30-Sep-2026, Dogwood Therapeutics has a trailing 12-month revenue of $100K.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 36,407 224,173 1,277 6,287
Revenue 100 0 0 0
EBITDA (27,866) (34,131) (12,246) (5,447)
Net Income (25,180) (34,257) (12,350) (5,296)
Total Assets 75,608 90,171 94,308 4,165
Total Debt 118 163 15,586 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Dogwood Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Dogwood Therapeutics‘s full profile, request access.

Request a free trial

Dogwood Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat p
Drug Discovery
Alpharetta, GA
8 As of 2025

Chatham, NJ
 

Bothell, WA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Dogwood Therapeutics Competitors (6)

One of Dogwood Therapeutics’s 6 competitors is Tonix Pharmaceuticals Holding, a Corporation company based in Chatham, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tonix Pharmaceuticals Holding Corporation Chatham, NJ
LeonaBio Formerly VC-backed Bothell, WA
Jasper Therapeutics Formerly VC-backed Redwood City, CA
Kezar Life Sciences Formerly VC-backed South San Francisco, CA
Paradigm Biopharmaceuticals Corporation Melbourne, Australia
To view Dogwood Therapeutics’s complete competitors history, request access »

Dogwood Therapeutics Patents

Dogwood Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023341167-A1 Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 Pending 16-Sep-2022
EP-4587120-A2 Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 Pending 16-Sep-2022
WO-2024059247-A2 Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 Inactive 16-Sep-2022
WO-2024059247-A3 Valacyclovir and celecoxib for the treatment of alzheimer's disease and covid-19 Inactive 16-Sep-2022
US-20130203781-A1 Aciclovir and celecoxib combination therapy for functional somatic syndromes Inactive 06-Feb-2012 A61K31/196
To view Dogwood Therapeutics’s complete patent history, request access »

Dogwood Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dogwood Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Dogwood Therapeutics‘s full profile, request access.

Request a free trial

Dogwood Therapeutics Acquisitions (2)

Dogwood Therapeutics’s most recent deal was a Merger/Acquisition with Pharmagesic (Holdings) for . The deal was made on 07-Oct-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pharmagesic (Holdings) 07-Oct-2024 Merger/Acquisition Drug Discovery
WEX Pharmaceuticals 07-Oct-2024 Merger/Acquisition Drug Discovery
To view Dogwood Therapeutics’s complete acquisitions history, request access »

Dogwood Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Dogwood Therapeutics’s complete esg history, request access »

Dogwood Therapeutics FAQs

  • When was Dogwood Therapeutics founded?

    Dogwood Therapeutics was founded in 2012.

  • Where is Dogwood Therapeutics headquartered?

    Dogwood Therapeutics is headquartered in Alpharetta, GA.

  • What is the size of Dogwood Therapeutics?

    Dogwood Therapeutics has 8 total employees.

  • What industry is Dogwood Therapeutics in?

    Dogwood Therapeutics’s primary industry is Drug Discovery.

  • Is Dogwood Therapeutics a private or public company?

    Dogwood Therapeutics is a Public company.

  • What is Dogwood Therapeutics’s stock symbol?

    The ticker symbol for Dogwood Therapeutics is DWTX.

  • What is the current stock price of Dogwood Therapeutics?

    As of 16-Nov-2026 the stock price of Dogwood Therapeutics is $1.05.

  • What is the current market cap of Dogwood Therapeutics?

    The current market capitalization of Dogwood Therapeutics is $40.5M.

  • What is Dogwood Therapeutics’s current revenue?

    The trailing twelve month revenue for Dogwood Therapeutics is $100K.

  • Who are Dogwood Therapeutics’s competitors?

    Tonix Pharmaceuticals Holding, LeonaBio, Jasper Therapeutics, Kezar Life Sciences, and Paradigm Biopharmaceuticals are some of the 6 competitors of Dogwood Therapeutics.

  • What is Dogwood Therapeutics’s annual earnings per share (EPS)?

    Dogwood Therapeutics’s EPS for 12 months was -$0.89.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process